Newsroom|Lundbeck US

Greening Lundbeck, Greening the Grid

Greening Lundbeck, Greening the Grid

With construction of a new solar park now complete, Lundbeck takes a step closer to net-zero emissions.

Healthy communities

0

ABOUT THE NEWSROOM

Here you will find media contacts, plus the latest news, stories and insights from Lundbeck US. Lundbeck is a global pharmaceutical company solely focused on the brain, and our 900+ U.S. employees are committed to improving the lives of people affected by psychiatric and neurological disorders.

Science

Perspective

our-impact

press-release

Tweets by LundbeckUS

Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI® (brexpiprazole) to Treat Schizophrenia in Pediatric Patients Ages 13-17

Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI® (brexpiprazole) to Treat Schizophrenia in Pediatric Patients Ages 13-17

0

New Analysis Finds Franklin County, Ohio Had Highest Percentage of Population Screen At-Risk for Psychotic-Like Experiences of All Large Counties in 2020 and 2021

New Analysis Finds Franklin County, Ohio Had Highest Percentage of Population Screen At-Risk for Psychotic-Like Experiences of All Large Counties in 2020 and 2021

0

Lundbeck reports positive results for VYEPTI® (eptinezumab-jjmr) from the DELIVER study in patients with migraine and prior preventive treatment failures

Lundbeck reports positive results for VYEPTI® (eptinezumab-jjmr) from the DELIVER study in patients with migraine and prior preventive treatment failures

Migraine

0

Lundbeck announced the start of a phase II clinical study to assess Lu AG09222 for migraine prevention

Lundbeck announced the start of a phase II clinical study to assess Lu AG09222 for migraine prevention

0

Lundbeck launches a phase II study for potential new treatment of multiple system atrophy

Lundbeck launches a phase II study for potential new treatment of multiple system atrophy

0